<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="343387">
  <stage>Registered</stage>
  <submitdate>13/12/2011</submitdate>
  <approvaldate>9/01/2012</approvaldate>
  <actrnumber>ACTRN12612000033842</actrnumber>
  <trial_identification>
    <studytitle>The effects of yoghurt and its probiotics on features of the metabolic syndrome, intestinal function, bone metabolism and quality of life; a randomised controlled trial.</studytitle>
    <scientifictitle>In elderly persons at risk of metabolic syndrome, is yoghurt and/or its probiotics efficacious at improving features of metabolic syndrome?</scientifictitle>
    <utrn>U1111-1123-9525</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Metabolic Syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Hypertension</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Arm 1: 200g/d Probiotic yoghurt consumed over a total of 6 weeks

Arm 2: 3 x probiotic capsules/d consumed over a total of 6 weeks. Each capsule contains &gt; 10 billion CFU probiotic bacteria</interventions>
    <comparator>Placebo arm 1: 250mL/d long-life milk consumed over a total of 6 weeks


Placebo arm 2: 3 x placebo capsules/dconsumed over a total of 6 weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Change in low density lipoprotein cholesterol assessed by blood analysis</outcome>
      <timepoint>Baseline and 6 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in systolic blood pressure assessed by sphygmomanometer</outcome>
      <timepoint>Baseline and 6 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change in fasting glucose concentration assessed by blood analysis</outcome>
      <timepoint>Baseline and 6 weeks after intervention commencement</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood glucose control as indicated by glycated haemoglobin, insulin concentration and fasting blood glucose level.</outcome>
      <timepoint>Baseline and 6 weeks after intervention commencement</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Gastrointestinal symptoms as assessed using the Irritable Bowel Syndrome Severity Scale</outcome>
      <timepoint>Baseline and 3 and 6 weeks after intervention commencement</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Minimal usual probiotic intake (consuming less than 400 g yoghurt per week, and not taking probiotic supplements); AND 2. BMI greater than 25 kg/m2; AND 3. Waist circumference greater than 94 cm in men and 80cm in women OR blood pressure &gt;120/80 mmHg</inclusivecriteria>
    <inclusiveminage>55</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Unlikely to complete the 6 week study
2. Intolerance to dairy foods
3. Unable to attend the study centre on 4 occasions over 9 weeks
4. Current antibiotic use
5. Patients on immunosuppressive
6. Type two diabetes requiring pharmaceutical treatment.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>To maintain blinding of both participants and researchers, the placebo and active capsules bottles will be provided to study staff labelled with only with the study number which will preassigned according to randomisation code - see below</concealment>
    <sequence>Participants will be randomly assigned to one of 4 intervention groups by computerised block randomisation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Factorial</assignment>
    <designfeatures>Participants will be blinded to capsule allocation, but not dairy allocation. The people assessing the outcomes and analysing results and data will be blinded to both capsule and dairy allocation</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>1/02/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>152</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>6000</postcode>
    <postcode>6003</postcode>
    <postcode>6004</postcode>
    <postcode>6005</postcode>
    <postcode>6006</postcode>
    <postcode>6007</postcode>
    <postcode>6008</postcode>
    <postcode>6009</postcode>
    <postcode>6010</postcode>
    <postcode>6011</postcode>
    <postcode>6014</postcode>
    <postcode>6015</postcode>
    <postcode>6016</postcode>
    <postcode>6017</postcode>
    <postcode>6018</postcode>
    <postcode>6050</postcode>
    <postcode>6051</postcode>
    <postcode>6052</postcode>
    <postcode>6059</postcode>
    <postcode>6060</postcode>
    <postcode>6100</postcode>
    <postcode>6101</postcode>
    <postcode>6102</postcode>
    <postcode>6150</postcode>
    <postcode>6151</postcode>
    <postcode>6152</postcode>
    <postcode>6153</postcode>
    <postcode>6154</postcode>
    <postcode>6156</postcode>
    <postcode>6157</postcode>
    <postcode>6158</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Richard Prince</primarysponsorname>
    <primarysponsoraddress>Bone and Vascular Research Group
1st Floor, C Block
Department of Endocrinology and Diabetes
Sir Charles Gairdner Hospital
Hospital Avenue, Nedlands WA 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Bone and Vascular Research Group</fundingname>
      <fundingaddress>the University of Western Australia
1st Floor, C Block
Department of Endocrinology and Diabetes
Sir Charles Gairdner Hospital
Hospital Avenue, Nedlands WA 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a 6 week randomised controlled factorial study to evaluate the effects of yoghurt and its probiotics on risk of metabolic syndrome, quality of life, gastrointestinal health and bone metabolism.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>the University of Western Australia Human Research Ethics Committee</ethicname>
      <ethicaddress>The University of Western Australia (M459)
Crawley, Perth
Western Australia 6009</ethicaddress>
      <ethicapprovaldate>27/07/2011</ethicapprovaldate>
      <hrec>RA/4/1/4873</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Kerry Ivey</name>
      <address>Bone and Vascular Research Group
1st Floor, C Block
Department of Endocrinology and Diabetes
Sir Charles Gairdner Hospital
Hospital Avenue, Nedlands WA 6009</address>
      <phone>+61 (08)  9346 3478</phone>
      <fax>+61 (08) 9346 1317</fax>
      <email>probioticstudy@meddent.uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kerry Ivey</name>
      <address>Bone and Vascular Research Group
1st Floor, C Block
Department of Endocrinology and Diabetes
Sir Charles Gairdner Hospital
Hospital Avenue, Nedlands WA 6009</address>
      <phone>+61 (08)  9346 3478</phone>
      <fax>+61 (08) 9346 1317</fax>
      <email>probioticstudy@meddent.uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Kerry Ivey</name>
      <address>Bone and Vascularl Research Group
1st Floor, C Block
Department of Endocrinology and Diabetes
Sir Charles Gairdner Hospital
Hospital Avenue, Nedlands WA 6009</address>
      <phone>+61 (08)  9346 3478</phone>
      <fax>+61 (08) 9346 1317</fax>
      <email>probioticstudy@meddent.uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>